Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Pasquier

Showing results (111-120 of 159) with videos related to

Pageof 16
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 31, 2025
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trialThomas Brion, Mamadou Balde, Rodrigue Allodji, et al.
International Journal of Cancer|August 12, 2023
CANTO skin: Evaluation of skin toxicity risk factors in patients treated for breast cancerSofiane Allali, Matthieu Carton, Sibille Everhard, et al.
Journal of Magnetic Resonance Imaging : JMRI|June 19, 2023
Efficiency and Accuracy Evaluation of Multiple Diffusion-Weighted MRI Techniques Across Different ScannersFrederik Crop, Clémence Robert, Romain Viard, et al.
European Urology|July 12, 2021
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate CancerStéphane Supiot, Loig Vaugier, David Pasquier, et al.
The Lancet. Oncology|October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trialPaul Sargos, Sylvie Chabaud, Igor Latorzeff, et al.
Journal of Geriatric Oncology|July 27, 2024
Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME databaseMathilde Cabart, Loïc Mourey, David Pasquier, et al.
European Radiology|October 31, 2025
Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAROsman Öcal, Christoph Johannes Zech, Maria Antonietta Bali, et al.
European Radiology|May 23, 2025
Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAROsman Öcal, Christoph Johannes Zech, Maria Antonietta Bali, et al.
International Journal of Radiation Oncology, Biology, Physics|December 18, 2018
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)Loig Vaugier, Clément Palpacuer, Emmanuel Rio, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2018
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug groupEmmanuel Meyer, David Pasquier, Guillemette Bernadou, et al.
Pageof 16

Showing results (111-120 of 159) with videos related to

Sort By:
Pageof 16
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 31, 2025
Comprehensive radiotherapy quality assurance analysis from individual DICOM data in the HypoG-01 phase 3 trialThomas Brion, Mamadou Balde, Rodrigue Allodji, et al.
International Journal of Cancer|August 12, 2023
CANTO skin: Evaluation of skin toxicity risk factors in patients treated for breast cancerSofiane Allali, Matthieu Carton, Sibille Everhard, et al.
Journal of Magnetic Resonance Imaging : JMRI|June 19, 2023
Efficiency and Accuracy Evaluation of Multiple Diffusion-Weighted MRI Techniques Across Different ScannersFrederik Crop, Clémence Robert, Romain Viard, et al.
European Urology|July 12, 2021
OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate CancerStéphane Supiot, Loig Vaugier, David Pasquier, et al.
The Lancet. Oncology|October 1, 2020
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trialPaul Sargos, Sylvie Chabaud, Igor Latorzeff, et al.
Journal of Geriatric Oncology|July 27, 2024
Real-world overview of therapeutic strategies and prognosis of older patients with advanced or metastatic non-small cell lung cancer from the ESME databaseMathilde Cabart, Loïc Mourey, David Pasquier, et al.
European Radiology|October 31, 2025
Correction: Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAROsman Öcal, Christoph Johannes Zech, Maria Antonietta Bali, et al.
European Radiology|May 23, 2025
Imaging in staging, treatment planning, and monitoring of hepatocellular carcinoma for local and locoregional therapies: consensus recommendations from EORTC and ESGAROsman Öcal, Christoph Johannes Zech, Maria Antonietta Bali, et al.
International Journal of Radiation Oncology, Biology, Physics|December 18, 2018
Early Toxicity of a Phase 2 Trial of Combined Salvage Radiation Therapy and Hormone Therapy in Oligometastatic Pelvic Node Relapses of Prostate Cancer (OLIGOPELVIS GETUG P07)Loig Vaugier, Clément Palpacuer, Emmanuel Rio, et al.
European Journal of Cancer (Oxford, England : 1990)|June 5, 2018
Stereotactic radiation therapy in the strategy of treatment of metastatic renal cell carcinoma: A study of the Getug groupEmmanuel Meyer, David Pasquier, Guillemette Bernadou, et al.
Pageof 16